Lexaria Expands into Transdermal, Grows Licensing Revenue
April 4th, 2018
Exclusive, News, Top Story
In the quickly expanding legal cannabis industry, effective delivery of the drug is an ongoing problem. Many consumers have taken to edible products as a healthier alternative to smoking, but there are still key issues with bioavailability and taste when infusing cannabinoids. Other delivery methods have gained in popularity as well, including topical creams and lotions. In addition to improving intestinal bio-absorption by as much as five to ten times in as little as 15 minutes, new laboratory study data has shown that the DehydraTECH™ technology is just as promising when it comes to transdermal applications.
Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQB: LXRP) DehydraTECH™ represents a breakthrough in cannabinoid drug delivery. Lexaria’s DehydraTECH™ is technology that promotes a molecular association between cannabinoids and certain fatty acid compounds that are known to have palatability and bio-absorption enhancing properties. This combination, in turn, results in improved cannabinoid taste, bioavailability and speed of effectiveness.
In March, the company announced the results from its first laboratory study of DehydraTECH™ on human skin at a California-based laboratory specializing in Franz diffusion cell skin permeability testing. Researchers compared the technology with two leading skin penetration enhancers, looking for penetration time, absorption quantity, and peak amounts of CBD absorbed into and through the skin at multiple testing intervals over 48 hours.
The researchers found that DehydraTECH™ was the fastest acting for absorption into the skin and demonstrated the highest overall average quantity of CBD delivered through the skin. In fact, the technology outperformed competing products by as much as 225%. The technology also lacked any odor, even without the use of perfumes, contrary to other cannabinoid industry products that can be quite odoriferous without the use of masking perfumes.
“We have theorized for some time that our DehydraTECH™ delivery system might have positive effects on skin-based delivery complementing its already commercialized gastro-intestinal product applications,” said Lexaria President John Docherty. “The first round of testing was very encouraging and showed clear benefits with regards to speed of action and, particularly, delivery of CBD across the skin barrier for potential transdermal applications.”
Building an IP Portfolio
Lexaria has already begun to commercialize the DehydraTECH™ delivery system, as well as build up its patent portfolio. Earlier this year, the company entered into two licensing agreements for the innovative platform with a cannabis edibles maker and a Canadian cannabis chocolate manufacturer. Under these agreements, the company has licensed out its technology for the development of edible products in exchange for licensing fees and royalties.
On March 22, the company announced that it received a Notice of Allowance from the U.S. Patent and Trademark Office providing for a “composition of matter” claims that protect the specific combination of substances which enable improved taste and bio-absorption. This adds to the company’s existing “method of use” patent that had previously been granted, further protects its delivery system, and opens the door to further commercialization.
“This Notice of Allowance applies to the delivery of both psychoactive and non-psychoactive cannabinoids as lipophilic active agents formulated together with the edible fatty acids that enable the powerful bioavailability and taste enhancing properties of the DehydraTECH™ technology,” said Mr. Docherty. “This allowance has been granted by the USPTO upon review of the compelling scientific data Lexaria has amassed.”
Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) represents a compelling investment opportunity in the cannabis industry. By solving a key issue facing many edibles manufacturers, the company hopes to license its technology to a growing number of companies in exchange for licensing fees and royalties. These high-margin revenues could unlock significant value for shareholders over the long-term.
For more information, visit the company’s website or download their investor presentation.
The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://www.cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.